SCHEMBL2968480

SCHEMBL2968480

CCCc1ccc2c(Nc3cc(Cl)cc(Oc4ccc(O)cc4)c3)ccnc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
ATM Q13315 1/20 0.41
MAPKAPK2 P49137 1/20 0.36
CYP2D6 P10635 6/20 0.36
CYP1A2 P05177 5/20 0.36
CYP2C8 P10632 4/20 0.36
CYP2C19 P33261 4/20 0.36
KCNH2 Q12809 4/20 0.36
CYP2C9 P11712 3/20 0.36
CYP3A4 P08684 3/20 0.36
OPRM1 P35372 2/20 0.34
ABCB11 O95342 1/20 0.34
APP P05067 1/20 0.34
CHRM2 P08172 1/20 0.34
HTR1A P08908 1/20 0.34
CHRM1 P11229 1/20 0.34
DRD2 P14416 1/20 0.34
ADRA2C P18825 1/20 0.34
SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2954855 0.89 SREBF2 (0.42) CYP1A2SREBF2KMT2ATDP1POLB
SCHEMBL2967892 0.81 MAOB (0.37) MAPTATMAPPNR4A2SREBF2
SCHEMBL2960139 0.78 SREBF2 (0.42) CYP1A2SREBF2KMT2ATDP1POLB
SCHEMBL2964171 0.73 PIM1 (0.45) MAPTGAAATMMAPKAPK2SREBF2
SCHEMBL2968674 0.72 NR4A2 (0.39) MAPTGAACYP2D6CYP1A2CYP2C8
SCHEMBL2970343 0.72 NR4A2 (0.39) MAPTGAACYP2D6CYP1A2CYP2C8
SCHEMBL2970337 0.72 NR4A2 (0.39) MAPTGAACYP2D6CYP1A2CYP2C8
SCHEMBL2968446 0.71 PTK6 (0.54) MAPTMAPKAPK2CYP2D6CYP1A2CYP2C19
SCHEMBL2960452 0.71 PIM1 (0.45)
SCHEMBL2962152 0.71 MAPT (0.39) MAPTKCNH2SLC6A2NR4A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 MAPT 1347/4885GAA 504/4885ATM 4463/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 MAPT 1347/4885GAA 504/4885ATM 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.